EVAX Evaxion A/S

NEUTRAL Impact: 3/10 6-K
Horizon weeks Filed Apr 27, 2026 Processed 1mo ago SEC 0001171843-26-002722
Notable filing: 6-K
Latest settled — T+20d ⚠ clustered
EVAX ▼ -1.67% at T+20d
NEUTRAL call ✗ call lost -1.67% · α vs SPY -6.63% · entry $4.18 → $4.11
Next anchor: T+60d in 6w
Last close $3.73 (close Jun 8) · -10.77% from $4.18 entry
Entry anchored
Apr 24, 02:04 PM ET
via Databento tick
T+1d
+3.35%
call +3.35% · α +3.83%
$4.32
settled 6w ago
T+5d
+9.33%
call +9.33% · α +8.93%
$4.57
settled 5w ago
T+20d
-1.67%
call -1.67% · α -6.63%
$4.11
settled 15d ago
T+60d
call — · α —
in 6w

Price Chart

Loading chart...

Executive Summary

Evaxion A/S announced the promotion of Birgitte Rn from Chief Scientific Officer (CSO) to a dual role as CSO and Chief Operating Officer (COO), citing organizational alignment and her long-standing operational and scientific contributions. The move is intended to enhance external engagement and strategy execution around its AI-Immunology platform.

Actionable Insight

Monitor upcoming earnings or pipeline updates for signs of improved operational execution or partnership activity that may result from the leadership change. Absent financial or strategic catalysts, this promotion is a routine internal realignment with limited near-term trading implications.

Key Facts

  • Birgitte Rn promoted from CSO to joint CSO and COO role at Evaxion A/S
  • Promotion follows internal management review aimed at improving external visibility and strategic execution
  • No changes to other executive roles; management team remains stable
  • No financial terms, compensation changes, or structural reorganization disclosed
  • Filing consists solely of a press release with no material financial or operational updates

Financial Impact

No immediate financial impact disclosed

operating_expensemanagement_compensation

Risk Factors

  • Expanded responsibilities without additional team changes could strain leadership capacity
  • Lack of external hires or structural changes may limit impact on investor engagement

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-002722
Exhibit: exh_991.htm0001171843-26-002722
Document: 0001171843-26-002722-index-headers.html0001171843-26-002722
Document: 0001171843-26-002722-index.html0001171843-26-002722
Document: 0001171843-26-002722.txt0001171843-26-002722
19 reports for EVAX
Performance horizon
100% Hit rate 6 of 6 directional calls best @ T+5▲ +22.94%Mar 5, 2026
Filters
Rows
Reports for EVAX — sortable, filterable
Type Now
May 12, 2026
28d ago
6-K
NEUTRAL ★ 3/10
$4.17 $4.09▼ −1.92%▼ −2.00%$3.73 (−10.55%)
May 12, 2026
28d ago
Press Release
NEUTRAL ★ 4/10
$4.17 $4.09▼ −1.92%▼ −2.00%$3.73 (−10.55%)
May 7, 2026
4w ago
6-K
NEUTRAL ★ 3/10
$4.07 $4.16▲ +2.21%▲ +0.71%$3.73 (−8.35%)
May 4, 2026
5w ago
Press Release
NEUTRAL ★ 1/10
$4.57 $4.23▼ −7.55%▼ −10.49%$3.73 (−18.38%)
Apr 27, 2026
6w ago
6-K
NEUTRAL ★ 3/10
$4.18 $4.57▲ +9.33%▲ +8.93%$3.73 (−10.77%)
Apr 27, 2026
6w ago
Press Release
NEUTRAL ★ 3/10
$4.18 $4.57▲ +9.33%▲ +8.93%$3.73 (−10.77%)
Apr 22, 2026
6w ago
6-K
NEUTRAL ★ 3/10
$4.27 $4.27· 0.00%▼ −0.05%$3.73 (−12.65%)
Apr 17, 2026
7w ago
6-K
BULLISH ★ 8/10
$4.45 $4.03▼ −9.44%▼ −9.99%$3.73 (−16.18%)
Apr 17, 2026
7w ago
6-K
BULLISH ★ 7/10
$4.45 $4.03▼ −9.44%▼ −9.99%$3.73 (−16.18%)
Apr 17, 2026
7w ago
Press Release
BULLISH ★ 7/10
$4.45 $4.03▼ −9.44%▼ −9.99%$3.73 (−16.18%)
Showing 10 of 19

US Market Status

Market Closed — Opens in 6h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access